NRIX earnings date and last-quarter result: next report 2026-10-08, last quarter miss, P/E -6.84. Updated 2026-07-23.
Nurix Therapeutics (NRIX) Research Hub
Nurix Therapeutics (NRIX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 25.55 USD (+0.83%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -6.84, market cap 2.04B. This hub links to the full technical, earnings and options research available for NRIX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 25.55 USD (+0.83%) |
| 52-week range | 16.8 USD – 28.23 USD |
| Trend regime | Range |
| 14-day RSI | 71 (Overbought) |
| Trailing P/E | -6.84 |
| Market cap | 2.04B |
| Dividend yield | 0.00% |
| Next earnings | 2026-10-08 |
Available research for NRIX
Covered Call on NRIX: how it works, illustrative setup around the real 25.55 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NRIX: how it works, illustrative setup around the real 25.55 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NRIX: how it works, illustrative setup around the real 25.55 USD price, max profit/loss, breakeven and when to use it. Educational.
NRIX technical analysis: range, last 25.55 USD, RSI 71, 52w range 16.8 USD–28.23 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is NRIX in?
Nurix Therapeutics (NRIX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NRIX in an uptrend or downtrend?
As of 2026-10-26, NRIX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NRIX's trailing P/E ratio?
NRIX's trailing P/E is -6.84, with a market cap of 2.04B. See the earnings research page for full valuation detail.
When does NRIX next report earnings?
NRIX is next scheduled to report earnings on 2026-10-08.